Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4246 Target Snapshot

Tyrosine-protein kinase Tec · SINGLE PROTEIN · Homo sapiens

1,366Compounds
297Assays
15Approved Drugs
766.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt P42680. Use UniProt P42680 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt P42680 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Tyrosine-protein kinase Tec as ChEMBL target CHEMBL4246, mapped to UniProt P42680. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Tyrosine-protein kinase Tec
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4246
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P42680
Tyrosine-protein kinase Tec
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Tyrosine-protein kinase Tec is the right protein anchor across sources, using UniProt P42680 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelTyrosine-protein kinase Tec
UniProt AccessionP42680
Component TypeProtein
Sequence Length631 aa

Tyrosine-protein kinase Tec

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Tyrosine-protein kinase Tec, mapped to UniProt P42680. Sequence length is 631 aa.

Mapped IDP42680
Review nameTyrosine-protein kinase Tec
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

15
Approved
10
Phase III
14
Phase II
9
Phase I
Assay Mix

Activity Type Distribution

IC50366.0
KI1.0
EC505.0
KD394.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5827965 10.1 IC50 0.08 Preclinical
CHEMBL4206765 10.05 IC50 0.09 Preclinical
CHEMBL4217959 10.0 IC50 0.1 Preclinical
CHEMBL4214683 9.96 IC50 0.11 Preclinical
CHEMBL5780981 9.92 IC50 0.12 Preclinical
CHEMBL5948251 9.82 IC50 0.15 Preclinical
CHEMBL5787507 9.8 IC50 0.16 Preclinical
CHEMBL4219011 9.8 IC50 0.16 Preclinical
CHEMBL5872571 9.74 IC50 0.18 Preclinical
CHEMBL5785815 9.72 IC50 0.19 Preclinical
Distribution

pChEMBL Value Distribution

4
5.0
20
5.5
40
6.0
56
6.5
75
7.0
40
7.5
65
8.0
64
8.5
23
9.0
16
9.5
pChEMBL
Approved Drugs

Approved Drugs

RITLECITINIB
CHEMBL4085457
Approved 2023
TIRABRUTINIB
CHEMBL4071161
Approved 2020
ZANUBRUTINIB
CHEMBL3936761
Approved 2019
ACALABRUTINIB
CHEMBL3707348
Approved 2017
OSIMERTINIB
CHEMBL3353410
Approved 2015
IBRUTINIB
CHEMBL1873475
Approved 2013
BOSUTINIB
CHEMBL288441
Approved 2012
DASATINIB
CHEMBL5416410
Approved 2006
Assay Landscape

Assay Landscape

297
Total Assays
342
Tested Compounds
2
Assay Types
Binding — 286 assays, 342 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 220 292 7.7
assay format 42 19 7.1
cell-based format 12 11 7.7
subcellular format 12 20 6.5
ADME — 11 assays, 13 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 5 9 8.4
assay format 4 2 7.0
cell-based format 2 2 7.0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine